Drug Transporter and Metabolizing Enzyme Gene Variants and Nonnucleoside Reverse-Transcriptase Inhibitor Hepatotoxicity
This nested case-control study examined relationships between MDR1, CYP2B6, and CYP3A4 variants and hepatotoxicity during antiretroviral therapy with either efavirenz- or nevirapine-containing regimens. Decreased risk of hepatotoxicity was associated with MDR1 3435C→;T (odds ratio, 0.254; P = .021)....
Gespeichert in:
| Veröffentlicht in: | Clinical infectious diseases 2006-09, Vol.43 (6), p.779-782 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 782 |
|---|---|
| container_issue | 6 |
| container_start_page | 779 |
| container_title | Clinical infectious diseases |
| container_volume | 43 |
| creator | Ritchie, Marylyn D. Haas, David W. Motsinger, Alison A. Donahue, John P. Erdem, Huso Raffanti, Stephen Rebeiro, Peter George, Alfred L. Kim, Richard B. Haines, Jonathan L. Sterling, Timothy R. |
| description | This nested case-control study examined relationships between MDR1, CYP2B6, and CYP3A4 variants and hepatotoxicity during antiretroviral therapy with either efavirenz- or nevirapine-containing regimens. Decreased risk of hepatotoxicity was associated with MDR1 3435C→;T (odds ratio, 0.254; P = .021). An interaction between MDR1 and hepatitis B surface antigen status predicted risk with 82% accuracy (P < .001). |
| doi_str_mv | 10.1086/507101 |
| format | Article |
| fullrecord | <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_19850738</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>4463934</jstor_id><oup_id>10.1086/507101</oup_id><sourcerecordid>4463934</sourcerecordid><originalsourceid>FETCH-LOGICAL-c548t-5c326707498252d49e0d8b47011280d93172066b60b8c1f2a6182113c29576a83</originalsourceid><addsrcrecordid>eNp1kV1rFDEUhgdRbK36C0RGQe9G8zH5upS2dov1A6ml9CZkMmdrtrPJmGS0219v2l26IHiVwPvwJOc9VfUco3cYSf6eIYERflDtYkZFw5nCD8sdMdm0ksqd6klKC4Qwlog9rnYwV5goxnerPwdxuqxPo_FpDDFDrI3v68-QTRcGd-P8ZX3ob1ZLqI_AQ31mojM-pzvqS_B-sgOE5Hqov8NviAmaO5eNbswmQX3sf7rO5RDrGYwmhxyunXV59bR6NDdDgmebc6_68fHwdH_WnHw9Ot7_cNJY1srcMEsJF0i0ShJG-lYB6mXXijIJkahXFAuCOO846qTFc2I4lgRjast0ghtJ96q3a-8Yw68JUtZLlywMg_EQpqSxkqU6egu-_gdchCn68jdNsFKs6NjWZmNIKcJcj9EtTVxpjPTtHvR6DwV8ubFN3RL6LbYpvgBvNoBJ1gzzUpp1actJJAnlpHCv1lyYxv8_9mLNLFIp-p5qW04VbUvcrGOXMlzfxyZeaS6oYHp2fqHx2Td0fvHpQAv6F86YsN4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>219955765</pqid></control><display><type>article</type><title>Drug Transporter and Metabolizing Enzyme Gene Variants and Nonnucleoside Reverse-Transcriptase Inhibitor Hepatotoxicity</title><source>Jstor Complete Legacy</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Ritchie, Marylyn D. ; Haas, David W. ; Motsinger, Alison A. ; Donahue, John P. ; Erdem, Huso ; Raffanti, Stephen ; Rebeiro, Peter ; George, Alfred L. ; Kim, Richard B. ; Haines, Jonathan L. ; Sterling, Timothy R.</creator><creatorcontrib>Ritchie, Marylyn D. ; Haas, David W. ; Motsinger, Alison A. ; Donahue, John P. ; Erdem, Huso ; Raffanti, Stephen ; Rebeiro, Peter ; George, Alfred L. ; Kim, Richard B. ; Haines, Jonathan L. ; Sterling, Timothy R.</creatorcontrib><description>This nested case-control study examined relationships between MDR1, CYP2B6, and CYP3A4 variants and hepatotoxicity during antiretroviral therapy with either efavirenz- or nevirapine-containing regimens. Decreased risk of hepatotoxicity was associated with MDR1 3435C→;T (odds ratio, 0.254; P = .021). An interaction between MDR1 and hepatitis B surface antigen status predicted risk with 82% accuracy (P < .001).</description><identifier>ISSN: 1058-4838</identifier><identifier>EISSN: 1537-6591</identifier><identifier>DOI: 10.1086/507101</identifier><identifier>PMID: 16912956</identifier><identifier>CODEN: CIDIEL</identifier><language>eng</language><publisher>Chicago, IL: The University of Chicago Press</publisher><subject>Adult ; Anti-HIV Agents - adverse effects ; Anti-HIV Agents - metabolism ; Anti-HIV Agents - therapeutic use ; Antiretroviral drugs ; Antiretrovirals ; Aryl Hydrocarbon Hydroxylases - genetics ; Benzoxazines ; Biological and medical sciences ; Biological variation ; Case-Control Studies ; Chemical and Drug Induced Liver Injury ; Cytochrome P-450 CYP2B6 ; Cytochrome P-450 CYP3A ; Cytochrome P-450 Enzyme System - genetics ; Dimensionality reduction ; Drug therapy ; Drug toxicity and drugs side effects treatment ; Exanthema ; Female ; Fever ; Genes ; Genes, MDR ; Genetic Variation ; Genotype ; Hepatitis ; Hepatitis antigens ; Hepatotoxicity ; HIV Infections - drug therapy ; HIV-1 ; HIV/AIDS ; Human genetics ; Humans ; Infectious diseases ; Liver - drug effects ; Liver Diseases - genetics ; Liver Diseases - virology ; Male ; Medical genetics ; Medical sciences ; Nevirapine - adverse effects ; Nevirapine - metabolism ; Nevirapine - therapeutic use ; Oxazines - adverse effects ; Oxazines - metabolism ; Oxazines - therapeutic use ; Oxidoreductases, N-Demethylating - genetics ; Pharmacology. Drug treatments ; Reverse transcriptase inhibitors ; Reverse Transcriptase Inhibitors - adverse effects ; Reverse Transcriptase Inhibitors - metabolism ; Reverse Transcriptase Inhibitors - therapeutic use ; Toxicity ; Toxicity: digestive system</subject><ispartof>Clinical infectious diseases, 2006-09, Vol.43 (6), p.779-782</ispartof><rights>Copyright 2006 The Infectious Diseases Society of America</rights><rights>2006 by the Infectious Diseases Society of America 2006</rights><rights>2006 INIST-CNRS</rights><rights>Copyright University of Chicago, acting through its Press Sep 15, 2006</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c548t-5c326707498252d49e0d8b47011280d93172066b60b8c1f2a6182113c29576a83</citedby><cites>FETCH-LOGICAL-c548t-5c326707498252d49e0d8b47011280d93172066b60b8c1f2a6182113c29576a83</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/4463934$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/4463934$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>314,776,780,799,27901,27902,57992,58225</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18082362$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16912956$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Ritchie, Marylyn D.</creatorcontrib><creatorcontrib>Haas, David W.</creatorcontrib><creatorcontrib>Motsinger, Alison A.</creatorcontrib><creatorcontrib>Donahue, John P.</creatorcontrib><creatorcontrib>Erdem, Huso</creatorcontrib><creatorcontrib>Raffanti, Stephen</creatorcontrib><creatorcontrib>Rebeiro, Peter</creatorcontrib><creatorcontrib>George, Alfred L.</creatorcontrib><creatorcontrib>Kim, Richard B.</creatorcontrib><creatorcontrib>Haines, Jonathan L.</creatorcontrib><creatorcontrib>Sterling, Timothy R.</creatorcontrib><title>Drug Transporter and Metabolizing Enzyme Gene Variants and Nonnucleoside Reverse-Transcriptase Inhibitor Hepatotoxicity</title><title>Clinical infectious diseases</title><addtitle>Clinical Infectious Diseases</addtitle><addtitle>Clinical Infectious Diseases</addtitle><description>This nested case-control study examined relationships between MDR1, CYP2B6, and CYP3A4 variants and hepatotoxicity during antiretroviral therapy with either efavirenz- or nevirapine-containing regimens. Decreased risk of hepatotoxicity was associated with MDR1 3435C→;T (odds ratio, 0.254; P = .021). An interaction between MDR1 and hepatitis B surface antigen status predicted risk with 82% accuracy (P < .001).</description><subject>Adult</subject><subject>Anti-HIV Agents - adverse effects</subject><subject>Anti-HIV Agents - metabolism</subject><subject>Anti-HIV Agents - therapeutic use</subject><subject>Antiretroviral drugs</subject><subject>Antiretrovirals</subject><subject>Aryl Hydrocarbon Hydroxylases - genetics</subject><subject>Benzoxazines</subject><subject>Biological and medical sciences</subject><subject>Biological variation</subject><subject>Case-Control Studies</subject><subject>Chemical and Drug Induced Liver Injury</subject><subject>Cytochrome P-450 CYP2B6</subject><subject>Cytochrome P-450 CYP3A</subject><subject>Cytochrome P-450 Enzyme System - genetics</subject><subject>Dimensionality reduction</subject><subject>Drug therapy</subject><subject>Drug toxicity and drugs side effects treatment</subject><subject>Exanthema</subject><subject>Female</subject><subject>Fever</subject><subject>Genes</subject><subject>Genes, MDR</subject><subject>Genetic Variation</subject><subject>Genotype</subject><subject>Hepatitis</subject><subject>Hepatitis antigens</subject><subject>Hepatotoxicity</subject><subject>HIV Infections - drug therapy</subject><subject>HIV-1</subject><subject>HIV/AIDS</subject><subject>Human genetics</subject><subject>Humans</subject><subject>Infectious diseases</subject><subject>Liver - drug effects</subject><subject>Liver Diseases - genetics</subject><subject>Liver Diseases - virology</subject><subject>Male</subject><subject>Medical genetics</subject><subject>Medical sciences</subject><subject>Nevirapine - adverse effects</subject><subject>Nevirapine - metabolism</subject><subject>Nevirapine - therapeutic use</subject><subject>Oxazines - adverse effects</subject><subject>Oxazines - metabolism</subject><subject>Oxazines - therapeutic use</subject><subject>Oxidoreductases, N-Demethylating - genetics</subject><subject>Pharmacology. Drug treatments</subject><subject>Reverse transcriptase inhibitors</subject><subject>Reverse Transcriptase Inhibitors - adverse effects</subject><subject>Reverse Transcriptase Inhibitors - metabolism</subject><subject>Reverse Transcriptase Inhibitors - therapeutic use</subject><subject>Toxicity</subject><subject>Toxicity: digestive system</subject><issn>1058-4838</issn><issn>1537-6591</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kV1rFDEUhgdRbK36C0RGQe9G8zH5upS2dov1A6ml9CZkMmdrtrPJmGS0219v2l26IHiVwPvwJOc9VfUco3cYSf6eIYERflDtYkZFw5nCD8sdMdm0ksqd6klKC4Qwlog9rnYwV5goxnerPwdxuqxPo_FpDDFDrI3v68-QTRcGd-P8ZX3ob1ZLqI_AQ31mojM-pzvqS_B-sgOE5Hqov8NviAmaO5eNbswmQX3sf7rO5RDrGYwmhxyunXV59bR6NDdDgmebc6_68fHwdH_WnHw9Ot7_cNJY1srcMEsJF0i0ShJG-lYB6mXXijIJkahXFAuCOO846qTFc2I4lgRjast0ghtJ96q3a-8Yw68JUtZLlywMg_EQpqSxkqU6egu-_gdchCn68jdNsFKs6NjWZmNIKcJcj9EtTVxpjPTtHvR6DwV8ubFN3RL6LbYpvgBvNoBJ1gzzUpp1actJJAnlpHCv1lyYxv8_9mLNLFIp-p5qW04VbUvcrGOXMlzfxyZeaS6oYHp2fqHx2Td0fvHpQAv6F86YsN4</recordid><startdate>20060915</startdate><enddate>20060915</enddate><creator>Ritchie, Marylyn D.</creator><creator>Haas, David W.</creator><creator>Motsinger, Alison A.</creator><creator>Donahue, John P.</creator><creator>Erdem, Huso</creator><creator>Raffanti, Stephen</creator><creator>Rebeiro, Peter</creator><creator>George, Alfred L.</creator><creator>Kim, Richard B.</creator><creator>Haines, Jonathan L.</creator><creator>Sterling, Timothy R.</creator><general>The University of Chicago Press</general><general>University of Chicago Press</general><general>Oxford University Press</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>7T2</scope><scope>7T7</scope><scope>7U7</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>K9.</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope></search><sort><creationdate>20060915</creationdate><title>Drug Transporter and Metabolizing Enzyme Gene Variants and Nonnucleoside Reverse-Transcriptase Inhibitor Hepatotoxicity</title><author>Ritchie, Marylyn D. ; Haas, David W. ; Motsinger, Alison A. ; Donahue, John P. ; Erdem, Huso ; Raffanti, Stephen ; Rebeiro, Peter ; George, Alfred L. ; Kim, Richard B. ; Haines, Jonathan L. ; Sterling, Timothy R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c548t-5c326707498252d49e0d8b47011280d93172066b60b8c1f2a6182113c29576a83</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Adult</topic><topic>Anti-HIV Agents - adverse effects</topic><topic>Anti-HIV Agents - metabolism</topic><topic>Anti-HIV Agents - therapeutic use</topic><topic>Antiretroviral drugs</topic><topic>Antiretrovirals</topic><topic>Aryl Hydrocarbon Hydroxylases - genetics</topic><topic>Benzoxazines</topic><topic>Biological and medical sciences</topic><topic>Biological variation</topic><topic>Case-Control Studies</topic><topic>Chemical and Drug Induced Liver Injury</topic><topic>Cytochrome P-450 CYP2B6</topic><topic>Cytochrome P-450 CYP3A</topic><topic>Cytochrome P-450 Enzyme System - genetics</topic><topic>Dimensionality reduction</topic><topic>Drug therapy</topic><topic>Drug toxicity and drugs side effects treatment</topic><topic>Exanthema</topic><topic>Female</topic><topic>Fever</topic><topic>Genes</topic><topic>Genes, MDR</topic><topic>Genetic Variation</topic><topic>Genotype</topic><topic>Hepatitis</topic><topic>Hepatitis antigens</topic><topic>Hepatotoxicity</topic><topic>HIV Infections - drug therapy</topic><topic>HIV-1</topic><topic>HIV/AIDS</topic><topic>Human genetics</topic><topic>Humans</topic><topic>Infectious diseases</topic><topic>Liver - drug effects</topic><topic>Liver Diseases - genetics</topic><topic>Liver Diseases - virology</topic><topic>Male</topic><topic>Medical genetics</topic><topic>Medical sciences</topic><topic>Nevirapine - adverse effects</topic><topic>Nevirapine - metabolism</topic><topic>Nevirapine - therapeutic use</topic><topic>Oxazines - adverse effects</topic><topic>Oxazines - metabolism</topic><topic>Oxazines - therapeutic use</topic><topic>Oxidoreductases, N-Demethylating - genetics</topic><topic>Pharmacology. Drug treatments</topic><topic>Reverse transcriptase inhibitors</topic><topic>Reverse Transcriptase Inhibitors - adverse effects</topic><topic>Reverse Transcriptase Inhibitors - metabolism</topic><topic>Reverse Transcriptase Inhibitors - therapeutic use</topic><topic>Toxicity</topic><topic>Toxicity: digestive system</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ritchie, Marylyn D.</creatorcontrib><creatorcontrib>Haas, David W.</creatorcontrib><creatorcontrib>Motsinger, Alison A.</creatorcontrib><creatorcontrib>Donahue, John P.</creatorcontrib><creatorcontrib>Erdem, Huso</creatorcontrib><creatorcontrib>Raffanti, Stephen</creatorcontrib><creatorcontrib>Rebeiro, Peter</creatorcontrib><creatorcontrib>George, Alfred L.</creatorcontrib><creatorcontrib>Kim, Richard B.</creatorcontrib><creatorcontrib>Haines, Jonathan L.</creatorcontrib><creatorcontrib>Sterling, Timothy R.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Industrial and Applied Microbiology Abstracts (Microbiology A)</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><jtitle>Clinical infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ritchie, Marylyn D.</au><au>Haas, David W.</au><au>Motsinger, Alison A.</au><au>Donahue, John P.</au><au>Erdem, Huso</au><au>Raffanti, Stephen</au><au>Rebeiro, Peter</au><au>George, Alfred L.</au><au>Kim, Richard B.</au><au>Haines, Jonathan L.</au><au>Sterling, Timothy R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Drug Transporter and Metabolizing Enzyme Gene Variants and Nonnucleoside Reverse-Transcriptase Inhibitor Hepatotoxicity</atitle><jtitle>Clinical infectious diseases</jtitle><stitle>Clinical Infectious Diseases</stitle><addtitle>Clinical Infectious Diseases</addtitle><date>2006-09-15</date><risdate>2006</risdate><volume>43</volume><issue>6</issue><spage>779</spage><epage>782</epage><pages>779-782</pages><issn>1058-4838</issn><eissn>1537-6591</eissn><coden>CIDIEL</coden><abstract>This nested case-control study examined relationships between MDR1, CYP2B6, and CYP3A4 variants and hepatotoxicity during antiretroviral therapy with either efavirenz- or nevirapine-containing regimens. Decreased risk of hepatotoxicity was associated with MDR1 3435C→;T (odds ratio, 0.254; P = .021). An interaction between MDR1 and hepatitis B surface antigen status predicted risk with 82% accuracy (P < .001).</abstract><cop>Chicago, IL</cop><pub>The University of Chicago Press</pub><pmid>16912956</pmid><doi>10.1086/507101</doi><tpages>4</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1058-4838 |
| ispartof | Clinical infectious diseases, 2006-09, Vol.43 (6), p.779-782 |
| issn | 1058-4838 1537-6591 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_19850738 |
| source | Jstor Complete Legacy; Oxford University Press Journals All Titles (1996-Current); MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Adult Anti-HIV Agents - adverse effects Anti-HIV Agents - metabolism Anti-HIV Agents - therapeutic use Antiretroviral drugs Antiretrovirals Aryl Hydrocarbon Hydroxylases - genetics Benzoxazines Biological and medical sciences Biological variation Case-Control Studies Chemical and Drug Induced Liver Injury Cytochrome P-450 CYP2B6 Cytochrome P-450 CYP3A Cytochrome P-450 Enzyme System - genetics Dimensionality reduction Drug therapy Drug toxicity and drugs side effects treatment Exanthema Female Fever Genes Genes, MDR Genetic Variation Genotype Hepatitis Hepatitis antigens Hepatotoxicity HIV Infections - drug therapy HIV-1 HIV/AIDS Human genetics Humans Infectious diseases Liver - drug effects Liver Diseases - genetics Liver Diseases - virology Male Medical genetics Medical sciences Nevirapine - adverse effects Nevirapine - metabolism Nevirapine - therapeutic use Oxazines - adverse effects Oxazines - metabolism Oxazines - therapeutic use Oxidoreductases, N-Demethylating - genetics Pharmacology. Drug treatments Reverse transcriptase inhibitors Reverse Transcriptase Inhibitors - adverse effects Reverse Transcriptase Inhibitors - metabolism Reverse Transcriptase Inhibitors - therapeutic use Toxicity Toxicity: digestive system |
| title | Drug Transporter and Metabolizing Enzyme Gene Variants and Nonnucleoside Reverse-Transcriptase Inhibitor Hepatotoxicity |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T15%3A11%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Drug%20Transporter%20and%20Metabolizing%20Enzyme%20Gene%20Variants%20and%20Nonnucleoside%20Reverse-Transcriptase%20Inhibitor%20Hepatotoxicity&rft.jtitle=Clinical%20infectious%20diseases&rft.au=Ritchie,%20Marylyn%20D.&rft.date=2006-09-15&rft.volume=43&rft.issue=6&rft.spage=779&rft.epage=782&rft.pages=779-782&rft.issn=1058-4838&rft.eissn=1537-6591&rft.coden=CIDIEL&rft_id=info:doi/10.1086/507101&rft_dat=%3Cjstor_proqu%3E4463934%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=219955765&rft_id=info:pmid/16912956&rft_jstor_id=4463934&rft_oup_id=10.1086/507101&rfr_iscdi=true |